
ADMA Biologics, Inc.
ADMA
ADMA: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
moreShow ADMA Financials
Recent trades of ADMA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ADMA's directors and management
Government lobbying spending instances
-
$10,000 Jul 19, 2023 Issue: Defense
-
$10,000 Apr 17, 2023 Issue: Defense
-
$10,000 Jan 18, 2023 Issue: Defense
-
$10,000 Oct 18, 2022 Issue: Defense
-
$10,000 Jul 14, 2022 Issue: Defense
-
$10,000 Apr 18, 2022 Issue: Defense
-
$10,000 Jan 18, 2022 Issue: Defense
-
$10,000 Oct 19, 2021 Issue: Health Issues Defense
-
$10,000 Apr 19, 2021 Issue: Health Issues Defense
New patents grants
-
Patent Title: Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Aug. 10, 2021
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Jun. 16, 2020
-
Patent Title: Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Apr. 16, 2019
-
Patent Title: Compositions and methods for the treatment of immunodeficiency May. 15, 2018
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Nov. 14, 2017
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Jul. 25, 2017
-
Patent Title: Compositions and methods for the treatment of immunodeficiency Aug. 18, 2015
Federal grants, loans, and purchases
Followers on ADMA's company Twitter account
Number of mentions of ADMA in WallStreetBets Daily Discussion
Recent insights relating to ADMA
Recent picks made for ADMA stock on CNBC
ETFs with the largest estimated holdings in ADMA
Flights by private jets registered to ADMA